Goldman Sachs’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.6M | Buy |
2,366,092
+205,810
| +10% | +$1.07M | ﹤0.01% | 3020 |
|
|
2025
Q4 | $13.3M | Buy |
2,160,282
+8,503
| +0.4% | +$61.7K | ﹤0.01% | 2792 |
|
|
2025
Q3 | $15.6M | Buy |
2,151,779
+868,325
| +68% | +$5.16M | ﹤0.01% | 2511 |
|
|
2025
Q2 | $6.82M | Buy |
1,283,454
+569,359
| +80% | +$3.36M | ﹤0.01% | 3122 |
|
|
2025
Q1 | $6.33M | Sell |
714,095
-56,316
| -7% | -$676K | ﹤0.01% | 3128 |
|
|
2024
Q4 | $10.6M | Sell |
770,411
-143,470
| -16% | -$2.65M | ﹤0.01% | 2752 |
|
|
2024
Q3 | $25M | Buy |
913,881
+36,007
| +4% | +$975K | ﹤0.01% | 1848 |
|
|
2024
Q2 | $21.5M | Sell |
877,874
-29,784
| -3% | -$654K | ﹤0.01% | 1837 |
|
|
2024
Q1 | $19.4M | Sell |
907,658
-180,331
| -17% | -$3.88M | ﹤0.01% | 1863 |
|
|
2023
Q4 | $20.8M | Sell |
1,087,989
-103,032
| -9% | -$1.78M | ﹤0.01% | 1842 |
|
|
2023
Q3 | $19.1M | Buy |
1,191,021
+16,461
| +1% | +$313K | ﹤0.01% | 1842 |
|
|
2023
Q2 | $27.2M | Sell |
1,174,560
-208,047
| -15% | -$4.54M | 0.01% | 1579 |
|
|
2023
Q1 | $32.1M | Sell |
1,382,607
-9,209
| -0.7% | -$187K | 0.01% | 1382 |
|
|
2022
Q4 | $20.2M | Sell |
1,391,816
-230,505
| -14% | -$4.29M | 0.01% | 1951 |
|
|
2022
Q3 | $31M | Buy |
1,622,321
+320,540
| +25% | +$7.36M | 0.01% | 1488 |
|
|
2022
Q2 | $23.7M | Sell |
1,301,781
-270,660
| -17% | -$5.62M | 0.01% | 1759 |
|
|
2022
Q1 | $39.6M | Sell |
1,572,441
-276,820
| -15% | -$7.08M | 0.01% | 1478 |
|
|
2021
Q4 | $51M | Sell |
1,849,261
-281,779
| -13% | -$8.16M | 0.01% | 1321 |
|
|
2021
Q3 | $68.8M | Sell |
2,131,040
-83,650
| -4% | -$2.78M | 0.01% | 1012 |
|
|
2021
Q2 | $67.7M | Buy |
2,214,690
+878,159
| +66% | +$25.4M | 0.02% | 1024 |
|
|
2021
Q1 | $40.7M | Sell |
1,336,531
-162,040
| -11% | -$4.6M | 0.01% | 1334 |
|
|
2020
Q4 | $29.6M | Buy |
1,498,571
+520,421
| +53% | +$8.4M | 0.01% | 1531 |
|
|
2020
Q3 | $12.8M | Sell |
978,150
-164,001
| -14% | -$2.08M | ﹤0.01% | 2106 |
|
|
2020
Q2 | $13M | Buy |
1,142,151
+581,899
| +104% | +$8.26M | ﹤0.01% | 2060 |
|
|
2020
Q1 | $8.02M | Buy |
560,252
+27,840
| +5% | +$588K | ﹤0.01% | 2249 |
|
|
2019
Q4 | $14.5M | Sell |
532,412
-63,895
| -11% | -$1.76M | ﹤0.01% | 2131 |
|
|
2019
Q3 | $17.1M | Sell |
596,307
-116,880
| -16% | -$3.41M | ﹤0.01% | 1908 |
|
|
2019
Q2 | $19.8M | Sell |
713,187
-59,336
| -8% | -$1.68M | 0.01% | 1858 |
|
|
2019
Q1 | $25.6M | Buy |
772,523
+229,068
| +42% | +$6.97M | 0.01% | 1656 |
|
|
2018
Q4 | $15.8M | Sell |
543,455
-179,437
| -25% | -$6.46M | 0.01% | 1986 |
|
|
2018
Q3 | $33.3M | Sell |
722,892
-347,950
| -32% | -$15.5M | 0.01% | 1523 |
|
|
2018
Q2 | $40M | Sell |
1,070,842
-506,461
| -32% | -$17.1M | 0.01% | 1377 |
|
|
2018
Q1 | $46.6M | Buy |
1,577,303
+737,577
| +88% | +$25M | 0.01% | 1241 |
|
|
2017
Q4 | $28.8M | Sell |
839,726
-52,490
| -6% | -$1.77M | 0.01% | 1670 |
|
|
2017
Q3 | $32.3M | Sell |
892,216
-109,228
| -11% | -$3.12M | 0.01% | 1607 |
|
|
2017
Q2 | $25.9M | Buy |
1,001,444
+51,247
| +5% | +$1.09M | 0.01% | 1734 |
|
|
2017
Q1 | $18.2M | Buy |
950,197
+77,991
| +9% | +$1.38M | 0.01% | 1948 |
|
|
2016
Q4 | $14.5M | Sell |
872,206
-569,412
| -39% | -$10.3M | ﹤0.01% | 2192 |
|
|
2016
Q3 | $29.7M | Buy |
1,441,618
+450,092
| +45% | +$11.4M | 0.01% | 1608 |
|
|
2016
Q2 | $30.3M | Buy |
991,526
+776,468
| +361% | +$27M | 0.01% | 1478 |
|
|
2016
Q1 | $8.05M | Buy |
215,058
+81,571
| +61% | +$3.07M | ﹤0.01% | 2385 |
|
|
2015
Q4 | $5.76M | Buy |
133,487
+33,438
| +33% | +$1.41M | ﹤0.01% | 2697 |
|
|
2015
Q3 | $3.75M | Sell |
100,049
-51,403
| -34% | -$1.82M | ﹤0.01% | 3149 |
|
|
2015
Q2 | $5.15M | Sell |
151,452
-189,229
| -56% | -$6.43M | ﹤0.01% | 2931 |
|
|
2015
Q1 | $12.1M | Sell |
340,681
-163,929
| -32% | -$5.87M | ﹤0.01% | 2136 |
|
|
2014
Q4 | $17.2M | Buy |
504,610
+242,468
| +92% | +$8.6M | 0.01% | 1920 |
|
|
2014
Q3 | $10.1M | Sell |
262,142
-131,991
| -33% | -$4.92M | ﹤0.01% | 2355 |
|
|
2014
Q2 | $15.3M | Buy |
394,133
+113,812
| +41% | +$4.23M | ﹤0.01% | 2013 |
|
|
2014
Q1 | $9.58M | Sell |
280,321
-388,637
| -58% | -$12M | ﹤0.01% | 2403 |
|
|
2013
Q4 | $14M | Sell |
668,958
-1,032,704
| -61% | -$26.1M | ﹤0.01% | 2052 |
|
|
2013
Q3 | $40M | Sell |
1,701,662
-104,123
| -6% | -$2.96M | 0.01% | 1114 |
|
|
2013
Q2 | $48.5M | Buy |
+1,805,785
| New | +$52.3M | 0.02% | 931 |
|
Other funds holding MYGN
O
GCM
VCM
VPM
Goldman Sachs's MYGN Position: Q1 2026 in Review
Goldman Sachs increased its Myriad Genetics (MYGN) stake by 9.5% in Q1 2026, buying an estimated $1.07M and bringing the position to 2,366,092 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3020.
Goldman Sachs first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $68.8M in Q3 2021. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.
- Goldman Sachs held 2,366,092 shares of Myriad Genetics worth $10.6M as of Q1 2026.
- Goldman Sachs bought 205,810 Myriad Genetics shares in Q1 2026, an estimated $1.07M.
- Myriad Genetics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3020 holding.
- Goldman Sachs first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Myriad Genetics position peaked at $68.8M in Q3 2021.
- 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.